Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c5 in Chinese Patients with Advanced Breast Cancer
NCT04852419Phase 1Completed
- Sponsor
- Zentera Therapeutics
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZN-c5 in estrogen receptor-positive breast cancer, sponsored by Zentera Therapeutics. Primary endpoints: Observed Dose Limited Toxicities at 28 days and Incidence of treatment-emergent adverse events. Started May 2021; status: completed.
02
Drugs
ZN-c5
03
Conditions
estrogen receptor-positive breast cancer
Beyond the preview
Go deeper on NCT04852419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04852419.